Studies and Clinical Trials
UCB TP0001: Phase II study; A multicentre, open-label study of TP0001 in adult patients with persistent/chronic ITP; Inclusion criteria: platelet count ≤30 x 109/L. UK principal investigator Dr Nichola Cooper, Imperial College Healthcare Trust, London (Enquiries to Camelia Vladescu, This email address is being protected from spambots. You need JavaScript enabled to view it. 020 331 34306)
PRTX-100 in ITP: Phase 1b study; A multicentre, open-label Study of PRTX-100 in adult patients with persistent/chronic ITP; Inclusion criteria: platelet count ≤30 x 109/L. UK principal investigator Dr Nichola Cooper, Imperial College Healthcare Trust, London (contact Camelia Vladescu, This email address is being protected from spambots. You need JavaScript enabled to view it. 020 331 34306)
FLIGHT Study: A multicentre randomised trial of first line treatment pathways for newly diagnosed Immune thrombocytopenia to compare standard steroid treatment against combined steroid and mycophenolate https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/flight . Chief investigator Dr Charlotte Bradbury, University Hospitals Bristol NHS Trust (Enquiries to Julie Pell – This email address is being protected from spambots. You need JavaScript enabled to view it., +44 (0)29 2074 4370)
MRI Study: Can subclinical brain micro haemorrhages be detected in patients with thrombocytopenia using susceptibility sensitive MRI in order to better direct treatment. Inclusion criteria: At least one count ≤30 x 109/L since diagnosis. Willing to travel to Hammersmith Hospital, London. (Enquiries to Camelia Vladescu, This email address is being protected from spambots. You need JavaScript enabled to view it. 020 331 34306)
Paediatric Romiplostim Study: A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP). This study is ongoing, but not recruiting participants.